The effects of proglumide on morphine induced motility changes

Area of Science:

• Neuropharmacology
• Gastroenterology
• Behavioral Science

Background:

• Cholecystokinin (CCK) is a peptide neurotransmitter implicated in various physiological processes, including pain modulation and gastrointestinal function.
• Opiates, such as morphine, are well-known for their analgesic properties and their effects on motor activity.
• The interaction between CCK and opioid systems is an area of ongoing research.

Purpose of the Study:

• To investigate the role of cholecystokinin (CCK) in modulating the effects of morphine on rat behavior.
• To determine if CCK antagonism influences morphine-induced hypokinesia (reduced motor activity).

Main Methods:

• Rats were administered proglumide, a CCK antagonist, at a dose of 0.02 mg/kg.
• Morphine was administered at varying doses (0, 5, 15, or 45 mg/kg) concurrently with or without proglumide.
• Behavioral activation and hypokinesia were assessed to evaluate the motor effects.

Main Results:

• Proglumide alone showed a trend towards increased behavioral activation in rats.
• Proglumide significantly potentiated the hypokinesia induced by morphine administration.
• These findings suggest a modulatory role for CCK in opioid-induced changes in motility.

Conclusions:

• Endogenous cholecystokinin (CCK) appears to tonically antagonize opioid modulation of motor activity.
• This antagonism is observed regardless of whether the opioid effects are mediated by endogenous or exogenous sources.
• CCK antagonists may alter the behavioral outcomes of opioid administration.